Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 11/20 | 0.69 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.64 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.64 |
| ▸ | PI4KA | P42356 | 3/20 | 0.59 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.59 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.59 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.59 |
| ▸ | ADCY5 | O95622 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.52 |
| ▸ | AHCY | P23526 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23513431 | 0.96 | ADORA2A (0.71) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL19841 | 0.90 | ADORA2A (0.69) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL1740530 | 0.88 | ADORA2A (0.67) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL13223800 | 0.84 | ADORA2A (0.48) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL4551803 | 0.84 | ADORA2A (0.91) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL28228476 | 0.82 | ADORA2A (0.88) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL21469779 | 0.82 | ADORA2A (0.88) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL1741560 | 0.82 | ADORA2A (0.88) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL23228230 | 0.82 | ADORA2A (0.88) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL28176129 | 0.82 | ADORA2A (0.88) | ADORA2AADORA1ADORA2BPI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9616099-B2 | Cyclosporin analogues for preventing or treating hepatitis C infection | ENANTA PHARMACEUTICALS, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9603895-B2 | Cyclosporin analogues for preventing or treating hepatitis C infection | ENANTA PHARMACEUTICALS, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20160136233-A1 | NOVEL CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION | ENANTA PHARM INC (US) | 2016-05-19 | — | — | US | disclosed |
| US-9221878-B2 | Cyclosporin analogues for preventing or treating hepatitis C infection | ENANTA PHARMACEUTICALS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150056165-A1 | NOVEL CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION | ENANTA PHARMACEUTICALS, INC. | 2015-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160136233-A1 | NOVEL CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION | HAVCR2, CHP1, MAVS | ADORA2A 2931/4885ADORA1 3172/4885ADORA2B 3857/4885 |
| US-20150056165-A1 | NOVEL CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION | HAVCR2, CHP1, MAVS | ADORA2A 2931/4885ADORA1 3172/4885ADORA2B 3857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.